www.nanemiar.eu



NANEMIAR

Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA

Funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme 2021-2027 under the Grant Agreement No 101080156

PARTNERS

Fundación para la Formación e Investigación Sanitarias de la Región de Murcia

IMIB Instituto Murciano de Investigación Biosanitaria Pascual Parrilla

Servicio Murciano de Salud

Mercurna

cnrs

ROUND TABLE WITH PATIENTS

When anemia cannot be treated with iron

People with congenital anemia do not produce red blood cells normally, which often leads to anemia (low red blood cell count) and excess iron in the body.

There are different types of congenital anemia and all of them are characterized by a deficiency in the production of functional red blood cells that, unfortunately, cannot be treated with iron supplements. These patients have deficiencies in specific proteins, hence the importance of research, with the aim of improving the lives of patients with this condition, whose prevalence in our society is considerably high and for which currently only supportive treatments exist.

The round table of physicians, patients, relatives, and researchers, organized within NANEMIAR project, wants to emphasize these diseases' existence and the need for new treatments

The research carried out by FFIS-IMIB Pascual Parrilla partner is focused on finding which proteins are altered in congenital anemias and to find new potential treatments for these diseases. The aim is to identify potential new treatments for these patients, since the current ones are supportive, and patients have many side effects derived from them.

In addition, a screening of potential drugs that inhibit these molecules is being carried out to serve as a treatment in congenital anemias; that is, in anemias that do not depend on iron levels.

NANEMIAR

Funded by the European Union